Illumina
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Illumina, Inc. specializes in delivering advanced genetic and genomic analysis tools, primarily through sequencing and array technologies. The company's offerings empower clients across various sector...
Latest News
2 hours ago · seekingalpha.com
Thrivent Mid Cap Stock Fund Q3 2026 Performance ReviewThrivent Mid Cap Stock Fund returned (2.92%) versus the Russell Mid Cap Index's (3.00%) return. Top contributors include Veeva Systems, Illumina and Zebra Tech. Top detractors include RH and UL Solutions.
6 days ago · marketbeat.com
Illumina Bets on Clinical Demand for Growth as Research Funding Uncertainty PersistsIllumina NASDAQ: ILMN expects clinical demand and sequencing consumables to remain central to its growth strategy, even as research customers continue to face uncertainty over grant funding, executives said at a UBS discussion.
6 days ago · seekingalpha.com
Illumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference TranscriptIllumina, Inc. (ILMN) Presents at 2026 UBS Global Healthcare Conference Transcript
8 days ago · prnewswire.com
Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technologyEarly access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow.
14 days ago · zacks.com
3 Stocks to Watch Following Guidance UpgradesThe Q3 earnings cycle continues to roll along, with several healthcare companies delivering positive results and raising their outlooks as a result.
14 days ago · prnewswire.com
Illumina selected to help bring precision medicine into everyday healthcare in SingaporeSG-INSIGHT study will extend whole-genome sequencing to nearly 1 in 10 Singapore residents, generating evidence to inform how precision medicine could be implemented in Singapore's healthcare system SINGAPORE, Nov. 2, 2026 /PRNewswire/ -- Illumina, Inc. (Nasdaq: ILMN) today announced it has been selected to provide whole-genome sequencing services for the SG-INSIGHT study, a cohort under Phase III of Singapore's National Precision Medicine (NPM) programme. Expected to include approximately one in 10 Singapore residents, or around 450,000 individuals, the study is designed to generate evidence from genomic and health data to help inform preventive approaches to healthcare.
15 days ago · zacks.com
Why Illumina (ILMN) is a Top Growth Stock for the Long-TermThe Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
15 days ago · zacks.com
Don't Overlook Illumina (ILMN) International Revenue Trends While Assessing the StockExplore Illumina's (ILMN) international revenue trends and how these numbers impact Wall Street's forecasts and what's ahead for the stock.
18 days ago · zacks.com
ILMN Q3 Earnings Call Highlights Higher Guidance and Clinical GrowthIllumina raises its 2026 guidance as strong clinical sequencing demand and NovaSeq X adoption fuel growth despite research weakness and pricing pressures.
18 days ago · zacks.com
Illumina (ILMN) Reports Q3 Earnings: What Key Metrics Have to SayAlthough the revenue and EPS for Illumina (ILMN) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove ILMN